- Home
- KZIA vs SPRC Comparison
KZIA vs SPRC Comparison
Compare KZIA & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- SPRC
- Stock Information
- Founded
- KZIA 1994
- SPRC 2004
- Country
- KZIA Australia
- SPRC Israel
- Employees
- KZIA N/A
- SPRC 3
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- SPRC Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- SPRC Health Care
- Exchange
- KZIA Nasdaq
- SPRC Nasdaq
- Market Cap
- KZIA 6.0M
- SPRC 4.8M
- IPO Year
- KZIA 1999
- SPRC N/A
- Fundamental
- Price
- KZIA $0.88
- SPRC $0.45
- Analyst Decision
- KZIA Strong Buy
- SPRC
- Analyst Count
- KZIA 2
- SPRC 0
- Target Price
- KZIA $11.50
- SPRC N/A
- AVG Volume (30 Days)
- KZIA 5.5M
- SPRC 837.4K
- Earning Date
- KZIA 03-26-2025
- SPRC 02-15-2025
- Dividend Yield
- KZIA N/A
- SPRC N/A
- EPS Growth
- KZIA N/A
- SPRC N/A
- EPS
- KZIA N/A
- SPRC N/A
- Revenue
- KZIA $1,655,324.00
- SPRC $1,747,000.00
- Revenue This Year
- KZIA N/A
- SPRC N/A
- Revenue Next Year
- KZIA N/A
- SPRC N/A
- P/E Ratio
- KZIA N/A
- SPRC N/A
- Revenue Growth
- KZIA 248000.00
- SPRC N/A
- 52 Week Low
- KZIA $0.85
- SPRC $0.20
- 52 Week High
- KZIA $15.80
- SPRC $4.29
- Technical
- Relative Strength Index (RSI)
- KZIA 29.00
- SPRC 43.71
- Support Level
- KZIA $0.90
- SPRC $0.43
- Resistance Level
- KZIA $1.60
- SPRC $0.55
- Average True Range (ATR)
- KZIA 0.14
- SPRC 0.06
- MACD
- KZIA 0.02
- SPRC -0.01
- Stochastic Oscillator
- KZIA 4.00
- SPRC 25.84
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About SPRC SciSparc Ltd.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.